potassium calcium-activated channel subfamily N member 2Genealiases: DYT34 · KCa2.2 · NEDMAB · SK2 · SKCA2 · SKCa 2
Q-omics provides the consensus-scored KCNN2 profile across patient tissues and cancer cell-line models. KCNN2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KCNN2 is differentially expressed in 15, with the highest sampling consensus in LIHC. Additionally, KCNN2 RNA expression shows 15,655 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LIHC, and TGCT as cancer lineages where KCNN2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNN2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNN2 survival associations across molecular data types. KCNN2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNN2 RNA expression–survival associations across cancer types. High KCNN2 expression shows unfavorable associations in MESO, SCLC and LUSC, but favorable associations in KIRC, UCEC and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for KCNN2 RNA expression.
This table summarizes KCNN2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KCNN2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNN2 shows lower tumor expression in LIHC, KICH, BLCA, LUSC and KIRP and higher tumor expression in BRCA. The LIHC box plot shows higher KCNN2 RNA expression in normal versus tumor tissue (log2 FC = −2.499, t-test p < 0.001).
This table shows molecular features associated with KCNN2 in patient tissues and cancer cell lines. In patient samples, KCNN2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNN2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BLOOD_Leukemia.
